- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06255431
EFFECTIVENESS AND SAFETY OF CREAM CONTAINING SPENT GRAIN WAX EXTRACT, ARGAN OIL, AND SHEA BUTTER POST-TRICHOLOROACETIC ACID 15% PEEL: RANDOMIZED, CONTROLLED, DOUBLE-BLIND, SPLIT-FACE CLINICAL TRIAL
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Jakarta, Indonesia, 10430
- Faculty of Medicine Universitas Indonesia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
women, 30 - 60 years old with facial skin aging underwent chemical peeling with TCA 15%, have received priming with topical retinoic acid 0.05%, for at least 2 weeks and its use has been discontinued three days before chemical peel.
Exclusion Criteria:
Pregnant or lactating women, patients who received hormonal therapy, immunosuppressants, allergic to any of treatment ingredients, had active skin diseases on the face (acne vulgaris, seborrheic dermatitis, dll), history of keloid/hypertrophic scar, open wound, active infection, or history of recurrent herpes simplex
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cream Containing Spent Grain Wax Extract, Argan Oil, and Shea Butter (Ezerra Cream)
Ezerra cream The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing. group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face). |
The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face). The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Other Names:
|
Placebo Comparator: Vehicle cream
Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.
The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing.
|
The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face). The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Transepidermal water loss
Time Frame: Baseline (30 minutes after peeling), day 3, and day 7
|
Baseline (30 minutes after peeling), day 3, and day 7
|
Skin Capacitance
Time Frame: Baseline (30 minutes after peeling), day 3, and day 7
|
Baseline (30 minutes after peeling), day 3, and day 7
|
Erythema index
Time Frame: Baseline (30 minutes after peeling), day 3, and day 7
|
Baseline (30 minutes after peeling), day 3, and day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
global investigator assessment
Time Frame: Baseline (30 minutes after peeling), day 3, and day 7
|
comprised individual ratings of erythema, desquamation, edema, each on 4-point-scale (0-None; 1-Mild; 2-Moderate, 3-Severe
|
Baseline (30 minutes after peeling), day 3, and day 7
|
subject self-assessment
Time Frame: Baseline (30 minutes after peeling), day 3, and day 7
|
comprised individual ratings of erythema, desquamation, burning, pain, and itch, each on a 4-point-scale (0-None; 1-Mild; 2-Moderate, 3-Severe).
|
Baseline (30 minutes after peeling), day 3, and day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dina Kusumawardhani, Indonesia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 23-02-0295
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging Disorder
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Central Hospital, Nancy, FranceCompleted
-
Federal University of ParaíbaUnknown
-
Istituto Auxologico ItalianoFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoCompletedAging | Equilibrium; Disorder, LabyrinthItaly
-
New York State Psychiatric InstituteCompletedCognitive Deterioration | Disorder of AgingUnited States
-
The Opole University of TechnologyRecruitingPrevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People (FRAILPOL)Frail Elderly Syndrome | Frailty | Aging | Frailty Syndrome | Aging Problems | Fragility | Aging Well | Aging DisorderPoland
-
Centre integre universitaire de sante et de services...Not yet recruitingAging | Disorder, Neurologic
-
University of AlbertaAlberta Health services; Glenrose FoundationActive, not recruitingHealthy | Frail Elderly Syndrome | Frailty | Healthy Aging | Frailty Syndrome | Aging Problems | Aging Disorder | Pre-FrailtyCanada
-
Centre for Addiction and Mental HealthLOFT Community ServicesRecruiting
Clinical Trials on Ezerra cream
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada
-
Incyte CorporationCompletedLichen SclerosusUnited States, Canada
-
Incyte CorporationRecruitingPrurigo NodularisSpain, Korea, Republic of, United States, Poland, Italy, Austria, Germany, Canada, Switzerland, Australia, France, Denmark, Bulgaria